IP Library Granted Patent US 12,583,821
Granted Patent B2
US 12,583,821 · App. 18/421,849 · Granted Mar 24, 2026

Salt of omecamtiv mecarbil and process for preparing salt

Inventors: Sheng Cui (Thousand Oaks, CA); Henry Morrison (Thousand Oaks, CA); Karthik Nagapudi (South San Francisco, CA); Shawn D. Walker (Woodland Hills, CA); Charles Bernard (Moorpark, CA); Karl Bennett Hansen (Cohasset, MA); Neil Fred Langille (Thousand Oaks, CA); Alan Martin Allgeier (Wilmington, DE); Steven M. Mennen (Thousand Oaks, CA); Jacqueline C. S. Woo (Sherwood Park, CA); Bradley Paul Morgan (Moraga, CA); Alex Muci (San Francisco, CA)
Assignee: CYTOKINETICS, INC.
C07D213/75A61K9/2013A61K9/2018A61K9/2054A61K31/496A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,583,821
App. No.
18/421,849
Granted
Mar 24, 2026
Kind
B2
Abstract

Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

Claims (44)

1 . A method of preparing omecamtiv mecarbil free base

comprising:

admixing methyl 4-(3-amino-2-fluorobenzyl) piperazine-1-carboxylate (Piperazine Aniline)

and phenyl (6-methylpyridin-3-yl)carbamate hydrochloride (Phenyl Carbamate·HCl)

in the presence of diisopropylethylamine and tetrahydrofuran.

2 . The method of claim 1 , wherein the phenyl (6-methylpyridin-3-yl)carbamate hydrochloride (Phenyl Carbamate·HCl)

is prepared by admixing Amino Pyridine

with phenyl chloroformate in acetonitrile and N-methyl-2-pyrrolidinone.

3 . The method of claim 1 , wherein the methyl 4-(3-amino-2-fluorobenzyl) piperazine-1-carboxylate (Piperazine Aniline)

is prepared by a process comprising:

step (i) neutralizing methyl 4-(2-fluoro-3-nitrobenzyl) piperazine-1-carboxylate hydrochloride (Piperazine Nitro·HCl)

with sodium bicarbonate in water and isopropyl acetate to yield methyl 4-(2-fluoro-3-nitrobenzyl) piperazine-1-carboxylate

step (ii) hydrogenating methyl 4-(2-fluoro-3-nitrobenzyl) piperazine-1-carboxylate in the presence of palladium on carbon in isopropyl acetate to form methyl 4-(3-amino-2-fluorobenzyl) piperazine-1-carboxylate; and

step (iii) isolating 4-(3-amino-2-fluorobenzyl) piperazine-1-carboxylate from isopropyl acetate and heptane.

4 . The method of claim 3 , wherein the methyl 4-(2-fluoro-3-nitrobenzyl) piperazine-1-carboxylate hydrochloride

is prepared by a process comprising:

step (i) admixing 2-fluoro-3-nitrotoluene (FN-Toluene)

with N-bromosuccinimide, benzoyl peroxide, and acetic acid to form a mixture;

step (ii) contacting the mixture from step (i) with diethylphosphite and diisopropylethylamine in methanol to form a solution of FN-bromide

step (iii) admixing the solution of FN-bromide from step (ii) with diisopropylethylamine, and piperazine carboxylate

in toluene to form a solution of Piperazine Nitro free base

and

step (iv) admixing the solution of Piperazine Nitro free base with IPA, water, and HCl to form methyl 4-(2-fluoro-3-nitrobenzyl) piperazine-1-carboxylate hydrochloride.

5 . A method of preparing omecamtiv mecarbil free base

comprising:

step (i) admixing 2-fluoro-3-nitrotoluene (FN-Toluene)

with N-bromosuccinimide, benzoyl peroxide, and acetic acid to form a mixture;

step (ii) contacting the mixture from step (i) with diethylphosphite and diisopropylethylamine in methanol to form a solution of FN-bromide

step (iii) admixing the solution of FN-bromide from step (ii) with diisopropylethylamine and piperazine carboxylate

in toluene to form a solution of Piperazine Nitro free base

and

step (iv) admixing the solution of Piperazine Nitro free base with IPA, water, and HCl to form methyl 4-(2-fluoro-3-nitrobenzyl) piperazine-1-carboxylate hydrochloride (Piperazine Nitro·HCl)

wherein the method further comprises:

step (v) neutralizing the Piperazine Nitro·HCl with sodium bicarbonate in water and isopropyl acetate to yield methyl 4-(2-fluoro-3-nitrobenzyl) piperazine-1-carboxylate

step (vi) hydrogenating methyl 4-(2-fluoro-3-nitrobenzyl) piperazine-1-carboxylate in the presence of palladium on carbon in isopropyl acetate to form methyl 4-(3-amino-2-fluorobenzyl) piperazine-1-carboxylate; and

step (vii) isolating 4-(3-amino-2-fluorobenzyl) piperazine-1-carboxylate from isopropyl acetate and heptane, to form methyl 4-(3-amino-2-fluorobenzyl) piperazine-1-carboxylate (Piperazine Aniline)

wherein the method further comprises:

step (viii) admixing Amino Pyridine

 with phenyl chloroformate in acetonitrile and N-methyl-2-pyrrolidinone to form phenyl (6-methylpyridin-3-yl)carbamate hydrochloride (Phenyl Carbamate·HCl)

 and

step (ix) admixing the Piperazine Aniline and the Phenyl Carbamate·HCl in the presence of diisopropylethylamine and tetrahydrofuran to form the omecamtiv mecarbil free base.

6 . The method of claim 3 , wherein the hydrogenating of step (ii) is in the presence of 5.0 wt % palladium on carbon.

7 . The method of claim 3 , wherein the hydrogenating of step (ii) is in a hydrogenator pressurized to 60±5 psig with hydrogen.

8 . The method of claim 3 , wherein the hydrogenating of step (ii) is at a temperature of 30±5° C.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2024
From: AMGEN INC.
To: CYTOKINETICS, INC.
Reel/Frame 066970/0022 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2024
From: ALLGEIER, ALAN MARTIN; BERNARD, CHARLES; CUI, SHENG; HANSEN, KARL BENNETT; LANGILLE, NEIL FRED; MENNEN, STEVEN; MORRISON, HENRY; NAGAPUDI, KARTHIK; WALKER, SHAWN D.; WOO, JACQUELINE C.S.
To: AMGEN INC.
Reel/Frame 066970/0057 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2024
From: MORGAN, BRADLEY PAUL; MUCI, ALEX
To: CYTOKINETICS, INC.
Reel/Frame 066970/0074 →
Continuity (8)
Continuation 17448833 · Sep 24, 2021
Continuation 17176003 · Feb 15, 2021
Continuation 16920155 · Jul 2, 2020
Continuation 16684216 · Nov 14, 2019
Continuation 15963529 · Apr 26, 2018
Division 14773436
Provisional Application 61785763 · Mar 14, 2013
Related Publication 20240317687A1 · Sep 26, 2024
References Cited (190)
US 6531469B1 · Rieu et al. · 2003 [cited by applicant]
US 7507735B2 · Morgan et al. · 2009 [cited by applicant]
US 7989455B2 · Morgan et al. · 2011 [cited by applicant]
US 8101617B2 · Morgan et al. · 2012 [cited by applicant]
US 8110595B2 · Morgan et al. · 2012 [cited by applicant]
US 8445495B2 · Morgan et al. · 2013 [cited by applicant]
US 8513257B2 · Morgan et al. · 2013 [cited by applicant]
US 8871768B2 · Morgan et al. · 2014 [cited by applicant]
US 8871769B2 · Morgan et al. · 2014 [cited by applicant]
US 9150564B2 · Morgan et al. · 2015 [cited by applicant]
US 9643925B2 · Morgan et al. · 2017 [cited by applicant]
US 9895308B2 · Caldwell · 2018 [cited by examiner]
US 9951015B2 · Bi et al. · 2018 [cited by applicant]
US 9988354B2 · Cui et al. · 2018 [cited by applicant]
US 10035770B2 · Morgan et al. · 2018 [cited by applicant]
US 10385023B2 · Morgan et al. · 2019 [cited by applicant]
US 10421726B2 · Bi et al. · 2019 [cited by applicant]
US 10543215B2 · Scott et al. · 2020 [cited by applicant]
US 10975034B2 · Morgan et al. · 2021 [cited by applicant]
US 11040956B2 · Caille et al. · 2021 [cited by applicant]
US 11384053B2 · Bi et al. · 2022 [cited by applicant]
US 11465969B2 · Morrison et al. · 2022 [cited by applicant]
US 11472773B2 · Cui et al. · 2022 [cited by applicant]
US 11576910B2 · Honarpour et al. · 2023 [cited by applicant]
US 11702380B2 · Caille et al. · 2023 [cited by applicant]
US 11753394B2 · Caille et al. · 2023 [cited by applicant]
US 11884630B2 · Bi et al. · 2024 [cited by applicant]
US 11926592B2 · Morrison · 2024 [cited by applicant]
US 11931358B2 · Honarpour · 2024 [cited by applicant]
US 11958809B2 · Cui · 2024 [cited by applicant]
US 11986474B1 · Malik et al. · 2024 [cited by applicant]
US 12162815B2 · Brasola et al. · 2024 [cited by applicant]
US 12194039B2 · Honarpour et al. · 2025 [cited by applicant]
US 12221417B2 · Cui et al. · 2025 [cited by applicant]
US 12264133B2 · Morgan et al. · 2025 [cited by applicant]
US 12269811B2 · Caille et al. · 2025 [cited by applicant]
US 12275704B2 · Bi et al. · 2025 [cited by applicant]
US 12295952B2 · Honarpour et al. · 2025 [cited by applicant]
US 20050096296A1 · Fikstad et al. · 2005 [cited by applicant]
US 20060014761A1 · Morgan et al. · 2006 [cited by applicant]
US 20070161617A1 · Morgan et al. · 2007 [cited by applicant]
US 20070208000A1 · Morgan et al. · 2007 [cited by applicant]
US 20080266044A1 · Nicoletti · 2008 [cited by applicant]
US 20090036447A1 · Morgan et al. · 2009 [cited by applicant]
US 20090099198A1 · Morgan et al. · 2009 [cited by applicant]
US 20090192168A1 · Muci et al. · 2009 [cited by applicant]
US 20100029680A1 · Morgan et al. · 2010 [cited by applicant]
US 20100087500A1 · Stover · 2010 [cited by applicant]
US 20110182947A1 · Appel et al. · 2011 [cited by applicant]
US 20120172372A1 · Morgan et al. · 2012 [cited by applicant]
US 20130324549A1 · Morgan et al. · 2013 [cited by applicant]
US 20140038983A1 · Morgan et al. · 2014 [cited by applicant]
US 20140309235A1 · Bi et al. · 2014 [cited by applicant]
US 20150005296A1 · Morgan et al. · 2015 [cited by applicant]
US 20160015628A1 · Caldwell · 2016 [cited by applicant]
US 20160016906A1 · Cui et al. · 2016 [cited by applicant]
US 20160115133A1 · Morgan et al. · 2016 [cited by applicant]
US 20170267638A1 · Morgan et al. · 2017 [cited by applicant]
US 20180140611A1 · Scott et al. · 2018 [cited by applicant]
US 20180273479A1 · Bi et al. · 2018 [cited by applicant]
US 20180305316A1 · Morgan et al. · 2018 [cited by applicant]
US 20180312469A1 · Cui et al. · 2018 [cited by applicant]
US 20190352267A1 · Morgan et al. · 2019 [cited by applicant]
US 20200079736A1 · Cui et al. · 2020 [cited by applicant]
US 20200108076A1 · Scott et al. · 2020 [cited by applicant]
US 20200155547A1 · Honarpour et al. · 2020 [cited by applicant]
US 20200277261A1 · Bi et al. · 2020 [cited by applicant]
US 20200308143A1 · Caille et al. · 2020 [cited by applicant]
US 20200331859A1 · Cui et al. · 2020 [cited by applicant]
US 20200399221A1 · Cui et al. · 2020 [cited by applicant]
US 20210198203A1 · Morgan et al. · 2021 [cited by applicant]
US 20210221771A1 · Morrison et al. · 2021 [cited by applicant]
US 20210292271A1 · Brasola et al. · 2021 [cited by applicant]
US 20210371397A1 · Caille et al. · 2021 [cited by applicant]
US 20220042055A1 · Bisagni et al. · 2022 [cited by applicant]
US 20220153700A1 · Cui et al. · 2022 [cited by applicant]
US 20220184068A1 · Honarpour et al. · 2022 [cited by applicant]
US 20220185779A1 · Morgan et al. · 2022 [cited by applicant]
US 20220298114A1 · Bi et al. · 2022 [cited by applicant]
US 20230044617A1 · Cui et al. · 2023 [cited by applicant]
US 20230090391A1 · Bi et al. · 2023 [cited by applicant]
US 20230108971A1 · Morrison et al. · 2023 [cited by applicant]
US 20230149394A1 · Honarpour et al. · 2023 [cited by applicant]
US 20230355615A1 · Honarpour et al. · 2023 [cited by applicant]
US 20230373955A1 · Caille et al. · 2023 [cited by applicant]
US 20240101517A1 · Cui · 2024 [cited by applicant]
US 20240199550A1 · Morrison et al. · 2024 [cited by applicant]
US 20240217933A1 · Bi et al. · 2024 [cited by applicant]
US 20250163023A1 · Caille et al. · 2025 [cited by applicant]
US 20250179005A1 · Brasola et al. · 2025 [cited by applicant]
US 20250205228A1 · Honarpour et al. · 2025 [cited by applicant]
US 20250243163A1 · Cui et al. · 2025 [cited by applicant]
US 20250255862A1 · Honarpour et al. · 2025 [cited by applicant]
CN 101035525A · 2007 [cited by applicant]
JP 2002535329A · 2002 [cited by applicant]
JP 2005507909A · 2005 [cited by applicant]
JP 2007510658A · 2007 [cited by applicant]
JP 2008503467A · 2008 [cited by applicant]
JP 2009516000A · 2009 [cited by applicant]
JP 2009519951A · 2009 [cited by applicant]
JP 2011520837A · 2011 [cited by applicant]
JP 2016502348A · 2016 [cited by applicant]
WO 2003032956A1 · 2003 [cited by applicant]
WO 2003032965A2 · 2003 [cited by applicant]
WO 2005041929A1 · 2005 [cited by applicant]
WO 2006009726A2 · 2006 [cited by applicant]
WO 2006009726A3 · 2006 [cited by applicant]
WO 2007054975A1 · 2007 [cited by applicant]
WO 2007059500A2 · 2007 [cited by applicant]
WO 2007070683A2 · 2007 [cited by applicant]
WO 2007059500A3 · 2007 [cited by applicant]
WO 2009138438A1 · 2009 [cited by applicant]
WO 2014085336A1 · 2014 [cited by applicant]
WO 2014152270A1 · 2014 [cited by applicant]
WO 2020011626A1 · 2020 [cited by applicant]
WO 2020014406A1 · 2020 [cited by applicant]
WO 2021053175A1 · 2021 [cited by applicant]
WO 2021053189A1 · 2021 [cited by applicant]
WO 2021070123A1 · 2021 [cited by applicant]
WO 2021070124A1 · 2021 [cited by applicant]
WO 2021136477A1 · 2021 [cited by applicant]
WO 2022177927A1 · 2022 [cited by applicant]
Decision of Technical Board of Appeal 3.3.02 of Mar. 7, 2024, dated Jun. 5, 2024, for European Patent No. 14720369.9/EP2970123, 24 pages. [cited by applicant]
Minutes of the Oral Proceeding T1107/22-3.3.02 3.3.02 of Mar. 7, 2024, for European Patent No. 14720369.9/EP2970123, 9 pages. [cited by applicant]
Newman, A. (Sep./Oct. 2011). “X-ray Powder Diffraction in Solid Form Screening and Selection”, American Pharmaceutical Review Sep./Oct. (6):44-51. [cited by applicant]
U.S. Appl. No. 18/939,410, filed Nov. 6, 2024, by Elena Brasola et al. (A copy of the U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. … [cited by applicant]
U.S. Appl. No. 18/642,005, filed Apr. 22, 2024, by Fady Malik et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.). [cited by applicant]
U.S. Appl. No. 18/967,331, filed Dec. 3, 2024, by Narimon Honarpour et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.). [cited by applicant]
U.S. Appl. No. 18/990,483, filed Dec. 20, 2024, by Sheng Cui et al. (A copy of the U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21,… [cited by applicant]
U.S. Appl. No. 19/029,911, filed Jan. 17, 2025, by Bi Mingda et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.). [cited by applicant]
U.S. Appl. No. 19/029,945, filed Jan. 17, 2025, by Caille Sebastien et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.). [cited by applicant]
Amendment in Response to Non-Final Office Action under 37 C.F.R. 1.111, dated Feb. 2, 2017 for U.S. Appl. No. 14/773,436, filed Sep. 8, 2015, 6 pages. [cited by applicant]
Anonymous. (2021). “Technical Report on Effects of OM Entities: Comparing the Physical Stability of OM Entities,” as submitted by patent proprietor Amgen and Cytokinetics, Inc. in a letter dated Aug. 1, 2021, 22 pages. [cited by applicant]
Badawy, S.I.F. et al. (May 2007). “Microenvironmental pH Modulation in Solid Dosage Forms,” Journal of Pharmaceutical Sciences 96(5):948-959. [cited by applicant]
Berge, S.M. et al. (Jan. 1977). “Pharmaceuticals Salts,” J. Pharmaceutical Sciences 66(1):1-19. [cited by applicant]
Brief Communication containing a Letter from the Proprietor of the Patent of Jan. 8, 2021 and Auxiliary Requests 1-7, from the EPO in EP2970123 dated Jan. 19, 2021, 62 pages. [cited by applicant]
Brief Communication regarding the Oral Proceedings and containing a Letter from the Opponent submitted Dec. 7, 2021, in the Opposition of EP Application No. EP14720369.9/EP2970123, 28 pages. [cited by applicant]
Brief Communication regarding the Oral Proceedings and containing a Letter from the Proprietor and Auxiliary Request 8-13, submitted Dec. 13, 2021, in the Opposition of EP Application No. EP14720369.9/EP2970123, 47 page… [cited by applicant]
Brief Communication regarding the Oral Proceedings and containing a Letter from the Proprietor submitted Oct. 15, 2021, in the Opposition of EP Application No. EP14720369.9/EP2970123, 8 pages. [cited by applicant]
Brittain, H.G. (2008). Theory and Origin of Polymorphism in Polymorphism in Pharmaceutical Solids, Brittain eds Marcel Decker, Inc., NY, NY, pp. 17-18, 4 pages. [cited by applicant]
Caira, M.R. (1998). “Crystalline Polymorphism of Organic Compounds,” in Design of Organic Solids. Topics in Current Chemistry, 198:163-208. [cited by applicant]
Carstensen, Advanced Pharmaceutical Solids, Drugs and Pharmaceutical Sciences, 110 New York: Marcel Dekker, Inc. (2001). [cited by applicant]
Chawla, G. et al. (Jan.-Mar. 2004). “Challenges in Polymorphism of Pharmaceuticals”, GRIPS 5(1):9-12. [cited by applicant]
Cleland, J.G.F. et al. (Aug. 20, 2011). “The Effects Of The Cardiac Myosin Activator, Omecamtivmecarbil, On Cardiac Function In Systolic Heart Failure: A Double-Blind, Placebo Controlled, Crossover, Dose-Ranging Phase 2… [cited by applicant]
Colorcon (2009). “An Introduction to METHOCEL, Premium Cellulose Esthers,” Colorcon, Version 2, 2 pages. [cited by applicant]
Communication of a Notice Opposition mailed May 20, 2020, signed May 14, 2020, by Opponent Keltie LLP against Granted European Patent Application EP14720369.9/EP2970123, filed by Amgen Inc. and Cytokinetics, 27 pages. [cited by applicant]
Communication of Summons to attend Oral Proceedings Pursuant to Rule 115(1)EPC (including Annex to the communication) in the opposition of EP Application No. EP14720369.9/EP2970123, mailed Mar. 30, 2021 11 pages. [cited by applicant]
Communication of the Board of Appeals Pursuant to Article 15(1) of the Rules of Procedure of the Board of Appeals, mailed Jan. 19, 2024, for EP Application No. EP14720369.9/EP2970123, 16 pages. [cited by applicant]
Declaration of Chunsheng QIAO for EP 2970123 dated and signed Oct. 14, 2021, 5 pages. [cited by applicant]
Declaration of Fady Malik for EP 2970123 dated and signed Dec. 13, 2021, 3 pages. [cited by applicant]
Declaration of Mingda Bi for EP 2970123 dated Jul. 1, 2021, 2 pages. [cited by applicant]
Declaration under 37 CFR 1.132 by inventor Mingda Bi dated and signed Jan. 12, 2016, for U.S. Appl. No. 14/210,713, filed Mar. 14, 2014, 4 pages. [cited by applicant]
Devane, J. (Mar. 8, 2013). “Impact of IVIVR on Product Development,” in In Vitro-in Vivo Correlations, Young, D. B. et al.eds., p. 246, 1 page. [cited by applicant]
Dow. (Jul. 2000). “Using METHOCEL Cellulose Ethers for Controlled Reliease of Drugs in Hydrophilic Matrix Systems,” WEB Brochure, located at https://www.colorcon.com/products-formulation/all-products/polymers-controlled… [cited by applicant]
Dow. “METHOCEL Cellulose Ethers, Technical Handbook”, located at https://cms.chempoint.com/ic/getattachment/2d8a4ff1-a232-46b7-b47d-956f2753cb3b/attachment.aspx last visited on Nov. 5, 2021, 32 pages. [cited by applicant]
European Search Report and Search Opinion for EP Patent Application No. EP20201011.2, filed Oct. 9, 2020, mailed Apr. 13, 2021, 8 pages. [cited by applicant]
Grounds of Appeal dated Jun. 20, 2022, for European Patent No. 2970123, Carpmaels & Ransford, Proprietors: Amgen Inc. and Cytokinteics, Inc. and Opponent Keltie LLP, 49 pages. [cited by applicant]
Grounds of Appeal dated Jun. 20, 2022, for European Patent No. 2970123, Opponent Keltie LLP, Patentee Amgen Inc. and Cytokinetics, Inc., 32 pages. [cited by applicant]
Gu et al., Grouping solvents by statistical analysis of solvent property parameters: Implication to polymorph screeninQ. Int. J. Pharmaceut. 283: 117-25 (2004). [cited by applicant]
Hellriegel, E.T. et al. (Dec. 1996). “Commentaries Interpatient Variability in Bioavailability is related to the extent of absorption: Implications for the Bioavailability and Bioequivalence Studies,” Clinical Pharmacol… [cited by applicant]
Hirayama, Organic Crystal production Manual: Principle and Know-How, Maruzen CO. Ltd. Japan (2008), 28 pages, no English abstract available. [cited by applicant]
Interlocutory Decision in Opposition Proceedings (Art. 101(3)(A) and 106(2) EPC), for European Application No. EP14720369.9/EP2970123, dated Feb. 10, 2022, 74 pages. [cited by applicant]
International Preliminary Report on Patentability issue date of Sep. 15, 2015, for Patent Application No. PCT/US2014/027104, filed Mar. 14, 2014, 7 pages. [cited by applicant]
International Preliminary Report on Patentability issue date of Sep. 15, 2015, for Patent Application No. PCT/US2014/027146, filed Mar. 14, 2014, 7 pages. [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority in connection with International Application No. PCT/US2014/027104, United States Patent Office, dated Mar. 14, 2015, 9 pages. [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority in connection with International Application No. PCT/US2014/027146, United States Patent Office, dated Mar. 14, 2014, 10 pages. [cited by applicant]
James, U.S. (Aug. 7, 1998). “Ritonavir Capsule Manufacturing Problems Will Require Switch To Liquid Formulation,” AIDS Treat News 300(1), Abstract Only, 1 page. [cited by applicant]
Malik, Fady, curriculum vitae dated Nov. 2021, 13 pages. [cited by applicant]
Minamivamado (Apr. 25, 1984). New pharmaceutics, pp. 102-103 and 232-233, 5 pages. [cited by applicant]
Newman et al., “Solid-state analysis of the active pharmaceutical ingredient in drug products”, DDT vol. 8, No. 19, Oct. 2003, p. 898-905. [cited by applicant]
Office Action issued in connection with Japanese Patent Application No. 2016-502348, dated Dec. 12, 2017. [cited by applicant]
Preliminary Communication about the Results of Oral Proceedings mailed Dec. 16, 2021, for EP Application No. EP14720369.9/EP2970123, 9 pages. [cited by applicant]
Reply to Appeal dated Nov. 4, 2022, for European Patent No. 2970123, Carpmaels & Ransford, Proprietors: Amgen Inc. and Cytokinteics, Inc. and Opponent Keltie LLP, 84 pages. [cited by applicant]
Reply to Notice of Appeal dated Nov. 4, 2022, for European Patent No. 2970123, Opponent Keltie LLP, Patentee Amgen Inc. And Cytokinetics, Inc., 112 pages. [cited by applicant]
Response to the Summons to Oral Proceedings mailed on Oct. 31, 2023, for EP Application No. EP14720369.9/EP2970123, 4 pages. [cited by applicant]
Rowe, R. C. et al. (2006). Handbook of Pharmaceutical Excipient, 5th edition, Pharmaceutical Press, 945 pages. [cited by applicant]
Second Declaration Under 37 CFR 1.132 of Mingda Bi, dated Jun. 24, 2016, 4 pages. [cited by applicant]
Siepe et al., “Strategies for the Design of Hydrophilic Matrix Tablets with Controlled 1 Microenvironmental oH”, Int. J. Pharm., 316(1-2):14-20 (2006). [cited by applicant]
Stahly, Journal of Pharmaceutical Science and Technology, Japan, 66(6):435-439 (2006). (No English Abstract Available). [cited by applicant]
Teerlink, J.R (Dec. 2009, e-pub. Feb. 21, 2009). “A Novel Approach to Improve Cardiac Performance: Cardiac Myosin Activators”, Heart Fail Rev. 14(4):289-298. [cited by applicant]
Teerlink, J.R. et al. (Aug. 20, 2011). “Dose-Dependent Augmentation Of Cardiac Systolic Function With The Selective Cardiac Myosin Activator, Omecamtiv Mecarbil: A First-In-Man Study,” Lancet 378(9792):667-675. [cited by applicant]
U.S. Appl. No. 15/898,303, filed Feb. 16, 2018, by William Brett Caldwell et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, … [cited by applicant]
U.S. Appl. No. 17/176,003, filed Feb. 15, 2021, by Sheng Cui et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.). [cited by applicant]
U.S. Appl. No. 18/416,741, filed Jan. 18, 2024, by Henry Morrison et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.). [cited by applicant]
U.S. Appl. No. 18/531,424, filed Dec. 6, 2023, by Mingda Bi et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.). [cited by applicant]
Mnogradova, E.V. et al. (Jul. 11, 2012). “Palladium-Catalyzed Cross-Coupling of Aryl Chlorides and Triflates with Sodium Cyanate: A Practical Synthesis of Unsymmetrical Ureas,” J. Am. Chem. Soc. 134(27):11132-11135, 11 … [cited by applicant]
Waggoner, P. (2020). “Average Relative Humidity,” Encyclopedia Britannica, as retrieved on Dec. 29, 2020, 4 pages. [cited by applicant]
WHO (2009). “Stability Testing Of Active Pharmaceutical Ingredients And Finished Pharmaceutical Products,” 43rd Report, Annex 2 in the World Health Organization (WHO) Technical Report Series, No. 953, 34 pages. [cited by applicant]
Brief Communication regarding the Interlocutory decision in Opposition proceedings dated Jun. 4, 2025, in the Opposition of EP Application No. EP14720369.9/EP2970123, 35 pages. [cited by applicant]
Notice of Pre-Grant Opposition mailed Nov. 24, 2025, for Indian Patent Application No. 3414/KOLNP/2015 and Written Opposition, 40 pages. [cited by applicant]